Alzheimer's disease; taking the edge off with cannabinoids?
Authors:
- 1 November 2007
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 152 (5) , 655-662
Abstract
Alzheimer's disease is an age‐related neurodegenerative condition associated with cognitive decline. The pathological hallmarks of the disease are the deposition of β‐amyloid protein and hyperphosphorylation of tau, which evoke neuronal cell death and impair inter‐neuronal communication. The disease is also associated with neuroinflammation, excitotoxicity and oxidative stress. In recent years the proclivity of cannabinoids to exert a neuroprotective influence has received substantial interest as a means to mitigate the symptoms of neurodegenerative conditions. In brains obtained from Alzheimer's patients alterations in components of the cannabinoid system have been reported, suggesting that the cannabinoid system either contributes to, or is altered by, the pathophysiology of the disease. Certain cannabinoids can protect neurons from the deleterious effects of β‐amyloid and are capable of reducing tau phosphorylation. The propensity of cannabinoids to reduce β‐amyloid‐evoked oxidative stress and neurodegeneration, whilst stimulating neurotrophin expression neurogenesis, are interesting properties that may be beneficial in the treatment of Alzheimer's disease. Δ9‐tetrahydrocannabinol can also inhibit acetylcholinesterase activity and limit amyloidogenesis which may improve cholinergic transmission and delay disease progression. Targeting cannabinoid receptors on microglia may reduce the neuroinflammation that is a feature of Alzheimer's disease, without causing psychoactive effects. Thus, cannabinoids offer a multi‐faceted approach for the treatment of Alzheimer's disease by providing neuroprotection and reducing neuroinflammation, whilst simultaneously supporting the brain's intrinsic repair mechanisms by augmenting neurotrophin expression and enhancing neurogenesis. The evidence supporting a potential role for the cannabinoid system as a therapeutic target for the treatment of Alzheimer's disease will be reviewed herewith.British Journal of Pharmacology (2007) 152, 655–662; doi:10.1038/sj.bjp.0707446; published online 10 September 2007Keywords
This publication has 87 references indexed in Scilit:
- The Endocannabinoid System and Neurogenesis in Health and DiseaseThe Neuroscientist, 2007
- Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activationMolecular and Cellular Neuroscience, 2007
- Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent propertiesBrain Research, 2007
- Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid ReceptorsBritish Journal of Pharmacology, 2007
- A Molecular Link between the Active Component of Marijuana and Alzheimer's Disease PathologyMolecular Pharmaceutics, 2006
- Role of the endocannabinoid system in Alzheimer's disease: New perspectivesLife Sciences, 2004
- Involvement of brain‐derived neurotrophic factor in cannabinoid receptor‐dependent protection against excitotoxicityEuropean Journal of Neuroscience, 2004
- Anandamide and noladin ether prevent neurotoxicity of the human amyloid-β peptideNeuroscience Letters, 2002
- Accumulation of the anandamide precursor and other N‐acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal deathJournal of Neurochemistry, 2001
- Effects of Dronabinol on anorexia and disturbed behavior in patients with Alzheimer's diseaseInternational Journal of Geriatric Psychiatry, 1997